Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aboufaycal, H. Articles by Jones, R. N. Search for Related Content PubMed PubMed Citation Articles by Aboufaycal, H. Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2007, p. 614-615, Vol. 45, No. 2
0095-1137/07/$08.00+0     doi:10.1128/JCM.01351-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

bla_VIM-2 and bla_VIM-7 Carbapenemase-Producing Pseudomonas aeruginosa Isolates Detected in a Tertiary Care Medical Center in the United States: Report from the MYSTIC Program

H. Aboufaycal,¹ H. S. Sader,^2,3 K. Rolston,^1* L. M. Deshpande,² M. Toleman,⁴ G. Bodey,¹ I. Raad,¹ and R. N. Jones^2,5

The University of Texas M.D. Anderson Cancer Center, Houston, Texas,¹ JMI Laboratories, North Liberty, Iowa,² Universidade Federal de Sao Paulo, Sao Paulo, Brazil,³ University of Bristol, Bristol, United Kingdom,⁴ Tufts University School of Medicine, Boston, Massachusetts⁵

Received 30 June 2006/ Returned for modification 26 August 2006/ Accepted 23 November 2006

Top Abstract Text References

 
Two Pseudomonas aeruginosa strains resistant to beta-lactams, fluoroquinolones, aminoglycosides, tetracyclines, and carbapenems and susceptible only to polymyxin B (MIC 2 µg/ml) were identified as part of the Meropenem Yearly Susceptibility Test Information Collection program. Metallo-ß-lactamase screening tests were positive, PCR yielded products with bla_VIM primers, and sequence analysis revealed bla_VIM-7 and bla_VIM-2. The isolates had distinct ribotype and pulsed-field gel electorphoresis patterns and appeared independently, remote in time and location, at the same cancer center.

Top Abstract Text References

 
Carbapenems are among the best choices for the treatment of infections caused by gram-negative bacilli. However, carbapenem resistance due to various mechanisms is being reported. Modifications in outer membrane permeability result in imipenem resistance, with low-grade meropenem resistance. Up-regulation of the efflux system likely affects meropenem and ertapenem more than imipenem. Hyperproduction of AmpC ß-lactamases with these two resistance mechanisms can further reduce carbapenem potency (7). A fourth mechanism is the production of carbapenemases which hydrolyze many ß-lactam antibiotics, including carbapenems (6). These enzymes have been detected among nonfermentative gram-negative bacilli as well as the Enterobacteriaceae (12).

Pseudomonas aeruginosa is a leading cause of nosocomial infections (9). It is a significant pathogen in cancer patients, and identification of carbapenem-resistant strains is a concern. The first metallo-ß-lactamase producing P. aeruginosa strain in the United States was reported from M. D. Anderson Cancer Center (MDACC) (10, 11). Here we report the characteristics and genetic relationships of two additional metallo-ß-lactamase producing P. aeruginosa strains from the same center compared to the index strain.

A total of 196 P. aeruginosa isolates were referred to JMI Laboratories (North Liberty, IA), from MDACC over a 7-year period (1999 to 2006) as part of the Meropenem Yearly Susceptibility Test Information Collection longitudinal surveillance program. Isolate identification was confirmed using standard biochemical tests and Vitek cards (bioMérieux, Hazelwood, MO). Antimicrobial susceptibility testing was performed using CLSI (formerly NCCLS)-described microdilution methodology (2). Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213 were used as quality control organisms for these experiments. Interpretations of susceptibilities for all agents tested were by CLSI criteria (2). Screening for metallo-ß-lactamase was performed by the disk approximation test using a modification of the procedure described by Arakawa et al. (1). Acinetobacter baumannii 54/97 (IMP-2 producer) was used as a positive control. Metallo-ß-lactamase E-test strips (AB BIODISK, Solna, Sweden) were used to confirm the disk approximation test results. Isolates exhibiting a positive disk approximation test for metallo-ß-lactamase were screened for IMP- and VIM-like genes using primers spanning the conserved sequences within the respective enzyme types. Metallo-ß-lactamases and their genetic contexts were studied by sequencing the gene segment accomplished using 5' and 3' conserved sequence primers from the class 1 integron as previously described. Sequences obtained were analyzed using NCBI BLAST search to determine the enzyme types.

Characteristics of the index case from 2001 have been previously described (10, 11). Two additional cases at the same institution (MDACC) occurred remote in time and location (July 2003 and January 2004) from the index case and each other. The P. aeruginosa strains isolated from these two cases were further characterized in the present study. Strains from the index case and case 3 (2004) were resistant to all ß-lactams as well as the aminoglycosides and fluoroquinolones as summarized in Table 1. The isolates were susceptible to polymyxin B. All three strains exhibited positive disk approximation tests to one or more ß-lactam substrates (imipenem, meropenem, or ceftazidime), and the recorded responses of all three strains were phenotypically different (Table 2). Generic bla_VIM primers yielded PCR products in both new cases. Sequencing results revealed bla_VIM-7 in the first position (5' end) of the integron amplified from strain 4623 (case 2), with the same genetic context as the index strain reported in 2001 (strain 7-406; case 1). bla_OXA-45 was identified in the index strain (not on the integron carrying bla_VIM-7) but was not present in strain 4623 (Table 2). Sequencing of the PCR amplicon obtained from strain 1-1852 (case 3) revealed bla_VIM-2, which has many key amino acid variations compared to bla_VIM-7, ruling out the possibility of simple evolution from the bla_VIM-7 gene pool that had previously been identified at MDACC. The VIM-7-producing strain in this study (strain 4623) and the index strain (strain 7-406) showed different ribotypes as well as pulsed-field gel electrophoresis patterns that were also distinct from the VIM-2-producing strains (1-1852).

View this table: [in this window] [in a new window]

TABLE 1. Antimicrobial agent susceptibilities of metallo-ß-lactamase-producing P. aeruginosa isolates from MDACC

View this table: [in this window] [in a new window]

TABLE 2. Summary of molecular epidemiologic investigations of metallo-ß-lactamase-producing P. aeruginosa isolated from MDACC

In the past few years there have been several reports of metallo-ß-lactamase-producing P. aeruginosa isolates from Europe, Latin America, and Asia (3, 4, 5, 12). This mechanism of carbapenem resistance remains uncommon in North America, with only a few published reports so far (11). Metallo-ß-lactamases have a broad spectrum of hydrolytic activity against amino-carboxyl- and ureidopenicillins, cephalosporins, cephamycins, and carbapenems but not monobactams (3). The VIM enzymes of this group are usually carried on mobile gene cassettes inserted into the class 1 integron, located chromosomally on a resistant plasmid. The VIM type of enzymes (VIM-1 to -11) were initially described for P. aeruginosa and Acinetobacter spp. and subsequently for Serratia marcescens, Pseudomonas putida, Pseudomonas stutzeri, Klebsiella pneumoniae, and E. coli, predominantly in Asia and Europe (3, 8). Analysis of molecular and epidemiological characterization combined with patient demographics leads to the following assumptions regarding the emergence of these VIM-type metallo-ß-lactamases at MDACC. (i) The VIM-7-producing index case appears to have arisen independently in the United States, possibly under pressure of carbapenem usage rather than by dissemination from Europe or Asia. (ii) bla_VIM-7 reemerged 2 years later in a clonally unrelated strain. Considering that the integron sequences of the strains isolated in this case and in the index case were identical, a horizontal transfer of the entire bla_VIM-7-containing integron probably occurred. (iii) The VIM-2-producing strain was isolated from a patient who may have been treated with carbapenems in Jordan. Although the carbapenemase gene pool in Jordan is not well known, bla_VIM-2 may be present, as it is widespread in Eastern Europe and Asia (4). However, bla_VIM-2 could also have been acquired in the United States. Although metallo-ß-lactamases generally do not hydrolyze aztreonam, all 3 strains were nonsusceptible to the monobactam, suggesting another mechanism of resistance (11).

Metallo-ß-lactamase-producing strains pose a serious threat to patients, mandating careful antibiotic stewardship and infection control programs. Additionally, the need for routine diagnostic smears for these enzymes (1, 4, 7) and the development of novel antimicrobial agents highly active against organisms producing these enzymes is paramount.

 
* Corresponding author. Mailing address: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. (Unit 402), Houston, TX 77030. Phone: (713) 792-6830. Fax: (713) 745-6839. E-mail: krolston{at}mdanderson.org.

Published ahead of print on 6 December 2006.

Top Abstract Text References

 

1
1. Arakawa, Y., N. Shibata, K. Shibayama, H. Kurokawa, T. Yagi, H. Fujiwara, and M. Goto. 2000. Convenient test for screening metallo-ß-lactamase-producing gram-negative bacteria by using thiol compounds. J. Clin. Microbiol. 38:40-43.[Abstract/Free Full Text]
2
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. CLSI, Wayne, PA.
3
3. Jacoby, G. A., and L. S. Munoz-Price. 2005. The new ß-lactamases. N. Engl. J. Med. 352:380-391.[Free Full Text]
4
4. Jones, R. N., D. J. Biedenbach, H. S. Sader, T. R. Fritsche, M. A. Toleman, and T. R. Walsh. 2005. Emerging epidemic of metallo-ß-lactamase-mediated resistances. Diagn. Microbiol. Infect. Dis. 51:77-84.[CrossRef][Medline]
5
5. Lee, K., J. B. Lim, J. H. Yum, D. Yong, Y. Chong, J. M. Kim, and D. M. Livermore. 2002. bla_VIM-2 cassette-containing novel integrons in metallo-ß-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob. Agents Chemother. 46:1053-1058.[Abstract/Free Full Text]
6
6. Luzzaro, F., A. Endimiani, J. D. Docquier, C. Mugnaioli, M. Bonsignori, G. Amicosante, G. M. Rossolini, and A. Toniolo. 2004. Prevalence and characterization of metallo-ß-lactamases in clinical isolates of Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 48:131-135.[CrossRef][Medline]
7
7. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.[Abstract/Free Full Text]
8
8. Riccio, M. L., L. Pallecchi, J. D. Docquier, S. Cresti, M. R. Catania, L. Pagani, C. Lagatolla, G. Cornaglia, R. Fontana, and G. M. Rossolini. 2005. Clonal relatedness and conserved integron structures in epidemiologically unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo-ß-lactamase from different Italian hospitals. Antimicrob. Agents Chemother. 49:104-110.[Abstract/Free Full Text]
9
9. Rolston, K. V. I., and J. J. 1999. Tarrand Pseudomonas aeruginosa-still a pathogen in patients with cancer. 11-year experience from a comprehensive cancer center. Clin. Infect. Dis. 29:463-464.[Medline]
10
10. Toleman, M. A., K. Rolston, R. N. Jones, and T. R. Walsh. 2004. bla_VIM-7, an evolutionarily distinct metallo-ß-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48:329-332.[Abstract/Free Full Text]
11
11. Toleman, M. A., K. Rolston, R. N. Jones, and T. R. Walsh. 2003. Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d' ß-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47:2859-2863.[Abstract/Free Full Text]
12
12. Walsh, T. R. 2005. The emergence and implications of metallo-ß-lactamases in gram-negative bacteria. Clin. Microbiol. Infect. 11(Suppl. 6):2-9.[Medline]

---

Journal of Clinical Microbiology, February 2007, p. 614-615, Vol. 45, No. 2
0095-1137/07/$08.00+0     doi:10.1128/JCM.01351-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Garza-Ramos, U., Morfin-Otero, R., Sader, H. S., Jones, R. N., Hernandez, E., Rodriguez-Noriega, E., Sanchez, A., Carrillo, B., Esparza-Ahumada, S., Silva-Sanchez, J. (2008). Metallo-{beta}-Lactamase Gene blaIMP-15 in a Class 1 Integron, In95, from Pseudomonas aeruginosa Clinical Isolates from a Hospital in Mexico. Antimicrob. Agents Chemother. 52: 2943-2946 [Abstract] [Full Text]  
• Martin, C. A., Morita, K., Ribes, J. A., Deshpande, L. M., Sader, H. S., Castanheira, M. (2008). IMP-15-Producing Pseudomonas aeruginosa Strain Isolated in a U.S. Medical Center: a Recent Arrival from Mexico. Antimicrob. Agents Chemother. 52: 2289-2290 [Full Text]  
• Queenan, A. M., Bush, K. (2007). Carbapenemases: the Versatile {beta}-Lactamases. Clin. Microbiol. Rev. 20: 440-458 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aboufaycal, H. Articles by Jones, R. N. Search for Related Content PubMed PubMed Citation Articles by Aboufaycal, H. Articles by Jones, R. N.